Mediar is an early-stage biotech firm working on developing treatments to stop, or potentially reverse, fibrosis. The company's platform and product development are centered around a new group of targets known as fibrotic mediators, which have significant influence on regulating myofibroblast biology and the formation of fibrosis in organs that have suffered chronic damage. Mediar's fundamental technology is rooted in innovative research conducted at Massachusetts General Hospital and Brigham and Women's Hospital. Established in 2018 by Partners Innovation Fund, the company is situated at Lab Central, the prominent biotech incubator in Cambridge.